Investigating how Angiopoietin-2 affects liver metastasis in pancreatic neuroendocrine tumors
Angiopoietin-2/Tie2 signaling regulation of liver metastasis in pancreatic neuroendocrine tumors
This study is looking at how a protein called Angiopoietin-2 affects the spread of pancreatic neuroendocrine tumors to the liver, and it aims to find out if blocking this protein can help slow down tumor growth and improve survival for patients with this type of cancer.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-10867490 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of Angiopoietin-2 (Ang2) in the development of liver metastases in patients with pancreatic neuroendocrine tumors (PanNET). The study aims to explore how Ang2 interacts with the Tie2 receptor to influence tumor growth and immune response, particularly in the context of the immunosuppressive environment that often accompanies these tumors. By using a mouse model, researchers will investigate whether inhibiting Ang2 can reduce liver metastasis and improve patient survival. This could lead to new therapeutic strategies for managing advanced PanNET.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with pancreatic neuroendocrine tumors, particularly those with or at risk of liver metastases.
Not a fit: Patients with non-pancreatic tumors or those without liver metastases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with metastatic pancreatic neuroendocrine tumors.
How similar studies have performed: Preliminary studies have shown promising results with Ang2 inhibition in mouse models, suggesting potential for success in similar approaches.
Where this research is happening
New York, United States
- Columbia University Health Sciences — New York, United States (Active)
Researchers
- Principal investigator: Kim, Minah — Columbia University Health Sciences
- Study coordinator: Kim, Minah
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.